Brief: Medigus Says Polyrizon Signed Deal With Nurexone
18/07/2022 14:12
July 18 (Reuters) - Medigus Ltd 2QMy.F :
* MEDIGUS: POLYRIZON SIGNED AN AGREEMENT WITH NUREXONE FOR
INTRANASAL ADMINISTRATION OF CUTTING - EDGE THERAPY FOR SPINAL
CORD INJURIES
* MEDIGUS - UNDER DEAL, NUREXONE WILL COVER COSTS OF
FORMULATION
DEVELOPMENT IN ESTIMATED AMOUNT OF $220,000 IN 3 INSTALLMENTS
UPON DEVELOPMENT SUCCESS
* MEDIGUS - NUREXONE BIOLOGIC EXPECTS TO BE ABLE TO PERFORM
A
BIOLOGICAL EFFICACY STUDY OF INTRANASAL SYSTEM WITHIN 3 QUARTERS
* MEDIGUS - MANUFACTURING AND MARKETING RIGHTS FOR
FORMULATIONS
UNDER COLLABORATION AGREEMENT ARE EXCLUSIVE TO NUREXONE
Source text for Eikon: ID:nGNX3l8SjQ
Further company coverage: 2QMy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement